UroGen Pharma Ltd. reported $189M of revenue over the trailing twelve months, +100% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $189M (to Q2 2026). Net income: −$98M, trailing twelve months to Q2 2026. Free cash flow: −$159M, trailing twelve months to Q2 2026. Operating margin: −47%, trailing twelve months to Q2 2026.

URGNUroGen Pharma Ltd.

Healthcare

$36.82+105% 1Y

$36.82

$16.4252 weeks$50.29

URGN as reported

UroGen Pharma Ltd. reported $189M of revenue over the trailing twelve months, +100% on the year before. 10 reported series are charted on this page, each one as filed.

$189M

Revenue, trailing twelve months · to Q2 2026 · +100% against the twelve months before

Net income: −$98M
Net income · −37% year on year · trailing twelve months to Q2 2026
Free cash flow: −$159M
Free cash flow · +29% year on year · trailing twelve months to Q2 2026
Operating margin: −47%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for URGN, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$189M	+100%	Q2 2026
Net income	−$98M	−37%	Q2 2026
EPS	−$4.96	n/a	Q4 2021 · 18 quarters behind
Gross margin	91%	n/a	Q2 2026
Operating margin	−47%	n/a	Q2 2026
Net margin	−64%	n/a	Q2 2026
ROE	117%	n/a	Q2 2026
ROA	−64%	n/a	Q2 2026
ROIC	85%	n/a	Q2 2026
Free cash flow	−$159M	+29%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.